Chiesi Farmaceutici SpA - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Chiesi Farmaceutici SpA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Chiesi Farmaceutici SpA - Product Pipeline Review - 2014', provides an overview of the Chiesi Farmaceutici SpA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Chiesi Farmaceutici SpA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Chiesi Farmaceutici SpA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Chiesi Farmaceutici SpA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Chiesi Farmaceutici SpA's pipeline products

Reasons to buy

- Evaluate Chiesi Farmaceutici SpA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Chiesi Farmaceutici SpA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Chiesi Farmaceutici SpA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Chiesi Farmaceutici SpA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chiesi Farmaceutici SpA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Chiesi Farmaceutici SpA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Chiesi Farmaceutici SpA Snapshot 5
Chiesi Farmaceutici SpA Overview 5
Key Information 5
Key Facts 5
Chiesi Farmaceutici SpA - Research and Development Overview 6
Key Therapeutic Areas 6
Chiesi Farmaceutici SpA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Chiesi Farmaceutici SpA - Pipeline Products Glance 16
Chiesi Farmaceutici SpA - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
Chiesi Farmaceutici SpA - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Chiesi Farmaceutici SpA - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Chiesi Farmaceutici SpA - Drug Profiles 20
(beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
meropenem 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CHF-6001 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
glycopyrrolate 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CHF-5633 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Drug for Cystic Fibrosis 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Agonize Glucocorticoid Receptor for Asthma and COPD 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Inhibit Caspase-2 for Neonatal Brain Injury 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule to target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit Neutrophil Elastases 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Chiesi Farmaceutici SpA - Pipeline Analysis 32
Chiesi Farmaceutici SpA - Pipeline Products by Target 32
Chiesi Farmaceutici SpA - Pipeline Products by Route of Administration 33
Chiesi Farmaceutici SpA - Pipeline Products by Molecule Type 34
Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action 35
Chiesi Farmaceutici SpA - Recent Pipeline Updates 36
Chiesi Farmaceutici SpA - Dormant Projects 37
Chiesi Farmaceutici SpA - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
carmoterol 38
indantadol 38
Chiesi Farmaceutici SpA - Company Statement 39
Chiesi Farmaceutici SpA - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Chiesi Farmaceutici SpA, Key Information 5
Chiesi Farmaceutici SpA, Key Facts 5
Chiesi Farmaceutici SpA - Pipeline by Indication, 2014 8
Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2014 9
Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2014 10
Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2014 11
Chiesi Farmaceutici SpA - Partnered Products in Pipeline, 2014 12
Chiesi Farmaceutici SpA - Partnered Products/ Combination Treatment Modalities, 2014 13
Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2014 14
Chiesi Farmaceutici SpA - Out-Licensed Products/ Combination Treatment Modalities, 2014 15
Chiesi Farmaceutici SpA - Phase III, 2014 16
Chiesi Farmaceutici SpA - Phase II, 2014 17
Chiesi Farmaceutici SpA - Phase I, 2014 18
Chiesi Farmaceutici SpA - Preclinical, 2014 19
Chiesi Farmaceutici SpA - Pipeline by Target, 2014 32
Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2014 33
Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2014 34
Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action, 2014 35
Chiesi Farmaceutici SpA - Recent Pipeline Updates, 2014 36
Chiesi Farmaceutici SpA - Dormant Developmental Projects,2014 37
Chiesi Farmaceutici SpA - Discontinued Pipeline Products, 2014 38
Chiesi Farmaceutici SpA, Subsidiaries 40